615P - Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)

MEK inhibition may overcome resistance to EGFR inhibition alone in patients (pts) with RAS wt mCRC. We evaluated the antitumor activity of T (MEK1/2 inhibitor) with Pmab (EGFR monoclonal antibody) in a phase II trial. Pts with KRAS, NRAS, and BRAF wt mCRC with prior 5-FU, irinotecan, oxaliplatin, +/...

Full description

Bibliographic Details

Published in:	Annals of oncology Vol. 30; pp. v232 - v233
Main Authors:	Alshammari, K., Aung, K.L., Zhang, T., Albiruni, A.R.R., Serra, S., Stockley, T., Wang, L., Nguyen, J., Spreafico, A., Hansen, A.R., Zwir, D., Siu, L.L., Bedard, P.
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01-10-2019
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!